| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 5.12 | 0.09 (+1.79%) | 4.26 - 7.55 | 93.9 thousand (Below Avg) |
Market data as of 4:00PM 06/18/13. Quotes are delayed by at least 15 min.
| Open | 5.03 |
|---|---|
| Previous Close | 5.03 |
| Day's Range | 5.00 - 5.14 |
| Market Cap | 155.5M |
| Avg Volume (10 Day) | 209.0K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.75 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
POZEN Announces FDA Acceptance of Filing of New Drug Application for PA32540/PA8140 Tablets
Business Wire - Wednesday 05/29/2013 7:30 AM ET
POZEN to Present at the Jefferies 2013 Global Healthcare Conference
Business Wire - Thursday 05/23/2013 7:30 AM ET
Presence of Gastric Erosions in Patients Taking Low-Dose Aspirin for Secondary Cardiovascular Prevention May Result in a 2-Fold Increase in Future Gastric Ulcers
Business Wire - Tuesday 05/21/2013 7:30 AM ET
| POZN | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -93.46% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 27.90 |
| Company | Last | Change |
|---|---|---|
| Pernix Therapeutics Holdings Inc | 3.88 | +4.30% |
| MEI Pharma Inc | 7.44 | -2.36% |
| Gentium SpA | 7.75 | -2.15% |
| Dynavax Technologies Corp | 1.04 | -5.45% |
| Cumberland Pharmaceuticals Inc | 5.04 | 0.00% |
Data is delayed by at least 15 min.